Additional Information

Description

Verzenio 150 mg Tablet (Blister Pack, 14 Tablets) contains abemaciclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor used in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. It is indicated for use in combination with endocrine therapy for advanced or metastatic breast cancer. By inhibiting CDK4/6, Verzenio disrupts cell cycle progression, leading to reduced tumor cell proliferation and delayed disease progression.

The medication is administered orally, with or without food, at a prescribed dose depending on the treatment regimen. Tablets should be swallowed whole without crushing, chewing, or splitting. Dose adjustments may be required based on individual tolerance and adverse reactions. Regular monitoring of complete blood counts and liver function is necessary to ensure patient safety and treatment efficacy.

Verzenio is associated with adverse effects such as diarrhea, neutropenia, fatigue, nausea, and decreased appetite. Serious risks include severe infections, hepatotoxicity, interstitial lung disease, and venous thromboembolism. Patients should be monitored for signs of infection, respiratory symptoms, and liver enzyme abnormalities.